American Society Of Addiction Medicine (ASAM) Assessment Practice Test

Duloxetine and venlafaxine are favored for treating depression in individuals who also experience comorbid pain conditions due to their dual action on both serotonin and norepinephrine pathways. Both of these medications are classified as serotonin-norepinephrine reuptake inhibitors (SNRIs), which can help alleviate depressive symptoms while also providing analgesic effects, making them particularly effective for patients dealing with chronic pain. Their effectiveness in managing both mood and pain symptoms makes them a practical choice in this co-occurring context. This multidimensional benefit is essential for holistic treatment in patients who have overlapping issues with depression and chronic pain. In contrast, other options may not exhibit the same level of efficacy in this unique combination of symptoms, as certain other classes of medications may not address pain as effectively.